

Effective Date: 9/15/2020
Reviewed: 6/2020, 4/2021, 3/2022, 3/2023, 4/2024, 3/2025
Scope: Medicaid

Descovy

POLICY

I. CRITERIA FOR APPROVAL

An authorization may be granted when all the following criteria are met:

- A. The patient has tried and failed emtricitabine/tenofovir disoproxil fumarate therapy due to one of the following:
- a. The member experienced side effects while utilizing emtricitabine/tenofovir disoproxil fumarate (i.e., decreased bone mineral density or renal toxicity); OR
 - b. The member has a contraindication or intolerance to emtricitabine/tenofovir disoproxil fumarate

II. QUANTITY LIMIT

- 30 tablets per 30 days

III. COVERAGE DURATION

- 12 months

IV. REFERENCES

1. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc.; January 2022.